CGT’s next obstacle: Securing the leukapheresis supply chain
In an exclusive webinar, experts from BBG Advanced Therapies explore how leukapheresis is emerging as a critical chokepoint for both autologous and allogeneic cell therapies – and whether new operating models, including a mobile leukapheresis centre, can help future‑proof the next wave of cell and gene therapies.
